Entropy Neurodynamics

Entropy Neurodynamics Equity Ratio

The Equity Ratio of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 87.83 %. In the previous year, Equity Ratio was 89.51 % — a change of -1.88% (lower).

Equity Ratio

87.83 %

YoY

-1.88%

Last updated:

Equity Ratio of Entropy Neurodynamics is 2026 87.83 % . Equity Ratio of Entropy Neurodynamics was 2025 89.51 % . It decreases by -1.88% lower compared to the previous year.

The Entropy Neurodynamics Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
94.80 AUD
Jan 1, 2020
76.69 AUD
Jan 1, 2021
87.93 AUD
Jan 1, 2022
64.70 AUD
Jan 1, 2023
70.17 AUD
Jan 1, 2024
75.41 AUD
Jan 1, 2025
89.51 AUD
Jan 1, 2026
87.83 AUD
The Entropy Neurodynamics Equity Ratio history
YEAREquity RatioYoY
87.83 %-1.88%
89.51 %+18.69%
75.41 %+7.46%
70.17 %+8.46%
64.70 %-26.42%
87.93 %+14.66%
76.69 %-19.10%
94.80 %-4,120.63%
-2.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Equity Ratio of Entropy Neurodynamics is 87.83 % in 2026.

Equity Ratio of Entropy Neurodynamics changed from 89.51 % to 87.83 %, representing a -1.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics